Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2020

View Archived Issues

AAV-ABCB4 gene therapy causes sustained reversal of PFIC3 disease biomarkers in mice

GM1 soluble oligosaccharide shows therapeutic potential for sporadic PD in B4galnt1+/- mice

African Americans' lung tumors have unstable genomes

Young blood not all it's cracked up to be

Initiation of first-in-human study of SBT-272

FDA clears IND application for KAN-101 for the treatment of celiac disease

TMPRSS11B as a new therapeutic target in NSCLC

Results from GLP preclinical study of AAV8-hCocH gene therapy

rVSVN4CT1-EBOVGP1 Ebola virus vaccine demonstrates safety and immunogenicity in phase I study

TWIST1 as a new risk gene for coronary artery disease and stroke

Multitrait analysis predicts glaucoma susceptibility, progression

Catalent patents decorin-containing products for cancer

Yale University divulges let-7 microRNA-activating compounds for endometriosis

AlzeCure Pharma discloses new Trk-A and Trk-B modulators

DFH Therapeutics and HHS describe betulinic acid derivatives for HIV infection

Boehringer Ingelheim presents GPR142 agonists

TNFAIP1 is a tumor suppressor in heptocellular carcinoma

Tepezza approved in the U.S. for thyroid eye disease

Signs of efficacy seen with ONCOS-102 and chemotherapy in mesothelioma trial

Phase I study of TAK-169 in relapsed or refractory multiple myeloma underway

Phase I study initiated for REN-001 in McArdle disease

Anti-IL6R Mab BCD-089 begins phase III rheumatoid arthritis study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...